LIVIVO - Search results -

Search results

Result 1 - 9 of total 9

Search options

Article ; Online: Degree of Breathiness in a Synthesized Voice Signal as it Differentiates Masculine versus Feminine Voices.

Whitling, Susanna / Botzum, Henry M / van Mersbergen, Miriam R

Journal of voice : official journal of the Voice Foundation

2023

Abstract: Introduction: Most studies determining speakers' perceived gender as binarily female or male are reliant on F0 perception, although other vocal parameters may also contribute to the perception of gender. The current study focused on the impact of ... ...

Abstract	Introduction: Most studies determining speakers' perceived gender as binarily female or male are reliant on F0 perception, although other vocal parameters may also contribute to the perception of gender. The current study focused on the impact of breathiness on the perception of speakers' gender as a biological variable (feminine or masculine). Methods: n = 31 normal hearing, native English speakers, 18 female, 13 male, mean age 23 (SD = 3.54), were auditorily and visually trained in and then took part in a categorical perception task. A continuum of nine samples of the word "hello", was created in an airway modulation model of speech and voice production. Resting vocal fold length, resting vocal fold thickness, F0, and vocal tract length were fixed. Glottal width at the vocal process, posterior glottal gap, and bronchial pressure were continually modified for all stimuli. Each stimulus was randomly presented 30 times within each of the five blocks (150 presentations in total). Participants rated stimuli as binarily female or male. Results: Showed a sigmoidal shift in breathiness along the continuum between perceived feminine or masculine voicing. This shift was evident at stimuli four and five, indicating a nonlinear, discrete perception of breathiness among participants. Response times were also significantly slower in these two stimuli, suggesting a categorical perception of breathiness among participants. Conclusion: Breathiness created by the change in glottal width of at least 0.21 cm may influence the perception of a speaker's perceived gender.
Language	English
Publishing date	2023-06-04
Publishing country	United States
Document type	Journal Article
ZDB-ID	17459-2
ISSN	1873-4588 ; 1557-8658 ; 0892-1997
ISSN (online)	1873-4588 ; 1557-8658
ISSN	0892-1997
DOI	10.1016/j.jvoice.2023.04.022
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4034: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Prophylactic effectiveness of tobramycin-dexamethasone eye drops compared with tobramycin/vehicle eye drops in controlling post-surgical inflammation in cataract patients : prospective, randomised, double-masked, two-arm, parallel-group, placebo-controlled, multicentre study.

Notivol, Ricardo / Amin, Dina / Whitling, Anna / Wells, David / Kennedy, Margaret / Cockrum, Paul C

Clinical drug investigation

2007 Volume 24, Issue 9, Page(s) 523–533

Abstract: Objective: To demonstrate the superiority of TobraDex((R)) (tobramycin 3 mg/mL, dexamethasone 1 mg/mL) eye drops over Tobrex((R)) (tobramycin 3 mg/mL)/vehicle (placebo) eye drops in the prophylaxis of inflammation after cataract surgery, and to provide ... ...

Abstract	Objective: To demonstrate the superiority of TobraDex((R)) (tobramycin 3 mg/mL, dexamethasone 1 mg/mL) eye drops over Tobrex((R)) (tobramycin 3 mg/mL)/vehicle (placebo) eye drops in the prophylaxis of inflammation after cataract surgery, and to provide additional safety data on TobraDex((R)). Setting: Twenty-two ophthalmology clinics from Brazil, Belgium, Germany, Ireland, Portugal, Spain and Sweden. Patients and methods: Prospective, randomised, double-masked, two-arm, parallel-group, placebo-controlled, multicentre study in 417 patients undergoing extracapsular cataract extraction with intraocular lens implantation. Patients were randomised (1 : 1) to TobraDex((R)) or to Tobrex((R))/vehicle. One drop of TobraDex((R)) or Tobrex((R)) was instilled in the operative eye (four times daily) on the day before surgery (day -1), one drop immediately following surgery in the operated eye (day 0), and then treatment (four times daily) was continued until day 7 (inclusive). From day 8 through day 21, patients in the TobraDex((R)) group continued with the same treatment, but patients in the Tobrex((R))/vehicle arm received the inactive ingredient only. Efficacy was assessed at 1, 3, 8, 14 and 21 days. The primary efficacy variable was the percentage of patients without post-surgical anterior chamber inflammation (i.e. with a sum of cells and flare scores of zero) on the day 8 visit. Results: TobraDex((R)) was significantly better (p < 0.05) than Tobrex((R))/vehicle in controlling post-surgical inflammation at day 8 as shown by the percentage of patients with an inflammation score of zero (51% vs 21%, respectively). The percentage of patients with treatment failure was 4% vs 16% (p < 0.001) in favour of TobraDex((R)). In the safety population (n = 415), 19% of patients reported a total of 52 adverse events while receiving TobraDex((R)) and 35.3% patients reported 103 adverse events while receiving Tobrex((R))/vehicle. One patient receiving Tobrex((R))/vehicle discontinued the study due to an ocular allergic reaction. No patient experienced clinically relevant changes in visual acuity, fundus parameters, cup/disc ratio or intraocular pressure related to treatment following the day of surgery. Conclusions: TobraDex((R)) eye drops were superior to Tobrex((R))/vehicle in controlling post-surgical inflammation following cataract extraction. TobraDex((R)) administered four times daily over 21 days post-surgery was safe and well tolerated in patients treated for the prevention of post-surgical inflammation following cataract extraction.
Language	English
Publishing date	2007-05-15
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	1220136-4
ISSN	1179-1918 ; 1173-2563 ; 0114-2402
ISSN (online)	1179-1918
ISSN	1173-2563 ; 0114-2402
DOI	10.2165/00044011-200424090-00003
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2807: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Comparing different routes and doses of phytonadione for reversing excessive anticoagulation.

Whitling, A M / Bussey, H I / Lyons, R M

Archives of internal medicine

1998 Volume 158, Issue 19, Page(s) 2136–2140

Abstract: Background: Significant controversy exists concerning how best to reverse excessive anticoagulation (due to warfarin sodium therapy) with phytonadione (vitamin K1) while avoiding overcorrection in patients who need to have anticoagulation therapy ... ...

Abstract	Background: Significant controversy exists concerning how best to reverse excessive anticoagulation (due to warfarin sodium therapy) with phytonadione (vitamin K1) while avoiding overcorrection in patients who need to have anticoagulation therapy maintained. Methods: A retrospective review of phytonadione use in reversing excessive anticoagulation was performed in 3 institutions. The effectiveness of low-dose (< or =0.5 mg) intravenous (LDIV), high-dose (1-10 mg) intravenous (HDIV), subcutaneous (1-10 mg) (SC), and oral (2.5 or 5 mg) (PO) phytonadione was evaluated within 48 hours of administration. Anticoagulation correction (international normalized ratio [INR], > or =2.0 and < or =5.0) occurred in 5 of 8 patients in the LDIV, 5 of 9 in the HDIV, 7 of 10 in the SC, and 5 of 6 in the PO groups. Correction was inadequate (INR >5.0) in 2 of 8 patients in the LDIV, 0 of 9 in the HDIV, 3 of 10 in the SC, and 1 of 6 in the PO groups. Overcorrection (INR <2.0) occurred in 1 patient in the LDIV, 4 patients in the HDIV, 0 in the SC, and 0 in the PO groups. Conclusions: Anticoagulation correction was achieved in most patients in all 4 groups. The HDIV method was most effective in lowering the INR to less than 5.0, but overcorrection occurred more frequently (4 patients in the HDIV vs 1 patient in the LDIV and 0 patients in the SC and PO groups). Failure to achieve an INR of less than 5.0 was a greater problem in the SC group (3 patients in the SC vs 2 patients in the LDIV and 1 patient in the PO groups). The LDIV and PO methods appear to be acceptable alternatives to the HDIV and SC methods currently recommended.
MeSH term(s)	Administration, Oral ; Aged ; Antifibrinolytic Agents/administration & dosage ; Female ; Humans ; Injections, Intravenous ; Injections, Subcutaneous ; International Normalized Ratio ; Male ; Medical Records ; Middle Aged ; Retrospective Studies ; Vitamin K 1/administration & dosage
Chemical Substances	Antifibrinolytic Agents ; Vitamin K 1 (84-80-0)
Language	English
Publishing date	1998-10-26
Publishing country	United States
Document type	Comparative Study ; Journal Article
ZDB-ID	211575-x
ISSN	1538-3679 ; 0003-9926 ; 0888-2479 ; 0730-188X
ISSN (online)	1538-3679
ISSN	0003-9926 ; 0888-2479 ; 0730-188X
DOI	10.1001/archinte.158.19.2136
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.119: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MA 14: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Comparison of topical tobramycin-dexamethasone with dexamethasone-neomycin-polymyxin and neomycin-polymyxin-gramicidin for control of inflammation after cataract surgery: results of a multicenter, prospective, three-arm, randomized, double-masked, controlled, parallel-group study.

Notivol, Ricardo / Bertin, Donata / Amin, Dina / Whitling, Anna / Kennedy, Margaret / Cockrum, Paul C

Clinical therapeutics

2004 Volume 26, Issue 8, Page(s) 1274–1285

Abstract: Background: Intraocular inflammation is typically treated with a combination of anti-inflammatory and anti-infective drugs. Tobramycin-dexamethasone (TD) has not been associated with any serious adverse events, indicating good tolerability.: Objective! ...

Abstract	Background: Intraocular inflammation is typically treated with a combination of anti-inflammatory and anti-infective drugs. Tobramycin-dexamethasone (TD) has not been associated with any serious adverse events, indicating good tolerability. Objective: The aims of this study were the following: (1) to demonstrate noninferiority of TD compared with dexamethasone-neomycin-polymyxin (DNP) in terms of anti-inflammatory efficacy, (2) to compare the anti-inflammatory efficacy of TD and DNP with that of a "placebo" control (antibiotic without anti-inflammatory agent), and (3) to provide additional safety data on TD. Methods: This prospective, double-masked, parallel-group study was conducted at 22 ophthalmology clinics across Europe and Brazil. Patients aged > 18 years undergoing cataract surgery were randomly assigned, in a 2:2:1 ratio, to receive tobramycin 3 mg/mL plus dexamethasone 1 mg/mL, dexamethasone 1 mg/mL plus neomycin sulfate 3500 IU/mL plus polymyxin B sulfate 6000 IU/mL, or neomycin sulfate 3500 IU/mL plus polymyxin B sulfate 7500 IU/mL plus gramicidin 20 microg/mL. All treatments were given as 1 drop instilled in the operated eye q.i.d. for 21 days. The primary efficacy end point, intraocular inflammation (determined using the sum of scores on anterior chamber cells and aqueous flare), was assessed at days 3, 8, 14, and 21 after surgery. Results: A total of 271 patients were enrolled (158 women, 113 men; age range 42-90 years) (TD, 104 patients; DNP, 110 patients; and neomycin-polymyxin-gramicidin [NPG], 57 patients). Intraocular inflammation was similar in the TD and DNP groups at all time points. At days 8, 14, and 21, inflammation scores were significantly lower with TD than with NPG (all, P < 0.05). At day 8, the inflammation score was significantly lower with DNP than with NPG (P < 0.05). A greater number of patients receiving NPG experienced treatment-related ocular allergic reactions compared with patients receiving TD (P < 0.05). One patient receiving TD (1.0%) and 5 given NPG (9.0%) were withdrawn due to ocular allergic reactions. None of the patients experienced an increase in intraocular pressure > or =10 mm Hg from baseline. Conclusions: In this study of patients undergoing cataract surgery combination therapy with TD was noninferior to DNP and was well tolerated.
MeSH term(s)	Administration, Topical ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/therapeutic use ; Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/therapeutic use ; Brazil ; Cataract Extraction ; Dexamethasone/administration & dosage ; Dexamethasone/therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Europe ; Female ; Gramicidin/administration & dosage ; Gramicidin/therapeutic use ; Humans ; Inflammation/pathology ; Inflammation/prevention & control ; Male ; Middle Aged ; Neomycin/administration & dosage ; Neomycin/therapeutic use ; Polymyxins/administration & dosage ; Polymyxins/therapeutic use ; Postoperative Complications/pathology ; Postoperative Complications/prevention & control ; Prospective Studies ; Tobramycin/administration & dosage ; Tobramycin/therapeutic use ; Treatment Outcome
Chemical Substances	Anti-Bacterial Agents ; Anti-Inflammatory Agents ; Polymyxins ; Gramicidin (1405-97-6) ; Dexamethasone (7S5I7G3JQL) ; Neomycin (I16QD7X297) ; Tobramycin (VZ8RRZ51VK)
Language	English
Publishing date	2004-09-16
Publishing country	United States
Document type	Clinical Trial ; Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
ZDB-ID	603113-4
ISSN	1879-114X ; 0149-2918
ISSN (online)	1879-114X
ISSN	0149-2918
DOI	10.1016/s0149-2918(04)80113-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1435: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 404: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Spironolactone-induced agranulocytosis.

Whitling, A M / Pérgola, P E / Sang, J L / Talbert, R L

The Annals of pharmacotherapy

1997 Volume 31, Issue 5, Page(s) 582–585

Abstract: Objective: To report a case of agranulocytosis secondary to spironolactone in a patient with cryptogenic liver disease.: Case summary: A 58-year-old Hispanic woman with cryptogenic cirrhosis was admitted to University Hospital on October 31, 1995. ... ...

Abstract	Objective: To report a case of agranulocytosis secondary to spironolactone in a patient with cryptogenic liver disease. Case summary: A 58-year-old Hispanic woman with cryptogenic cirrhosis was admitted to University Hospital on October 31, 1995. Laboratory data revealed a leukocyte count of 1.0 x 10(3)/mm3 and an absolute neutrophil count (ANC) of 10 cells/mm3. Prior to treatment with spironolactone, the leukocyte count was 10.2 x 10(3)/mm3 and ANC 8400 cells/mm3. Agranulocytosis resolved 5 days following the discontinuation of spironolactone. Results from the bone marrow biopsies before and after treatment with spironolactone suggested that agranulocytosis was caused by the drug's toxic effect on the bone marrow. Discussion: Drug-induced agranulocytosis is a serious adverse effect, occurring at a rate of approximately 6.2 cases per million persons each year. In addition to the case reported here, three other reports of agranulocytosis secondary to spironolactone have been published in the literature. Several factors have been identified that may increase a patient's risk for developing agranulocytosis, including increased age, hepatic or renal impairment, drug dosage and duration, and concurrent medications. Conclusions: Agranulocytosis secondary to spironolactone is a serious potential adverse effect. Patients with risk factors for developing this adverse effect should be closely monitored since early detection and discontinuation of spironolactone can improve prognosis.
MeSH term(s)	Agranulocytosis/chemically induced ; Agranulocytosis/pathology ; Bone Marrow/pathology ; Diuretics/adverse effects ; Female ; Granulocytes ; Humans ; Leukocyte Count ; Middle Aged ; Risk Factors ; Spironolactone/adverse effects
Chemical Substances	Diuretics ; Spironolactone (27O7W4T232)
Language	English
Publishing date	1997-05
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	1101370-9
ISSN	1542-6270 ; 1060-0280
ISSN (online)	1542-6270
ISSN	1060-0280
DOI	10.1177/106002809703100511
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 900: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate.

Patel, Deepen / Garadi, Rekha / Brubaker, Michael / Conroy, J Peter / Kaji, Yoshiko / Crenshaw, Krista / Whitling, Anna / Wall, G Michael

Allergy and asthma proceedings

2007 Volume 28, Issue 5, Page(s) 592–599

Abstract: Rapid relief of symptoms should be one of the primary goals of treatment for allergic rhinitis (AR). The onset and duration of action of olopatadine hydrochloride nasal spray, 665 mcg (OLO; Patanese), for seasonal AR (SAR) was evaluated in this study. ... ...

Abstract	Rapid relief of symptoms should be one of the primary goals of treatment for allergic rhinitis (AR). The onset and duration of action of olopatadine hydrochloride nasal spray, 665 mcg (OLO; Patanese), for seasonal AR (SAR) was evaluated in this study. This study was performed to determine the onset and duration of action of OLO compared with placebo spray, with mometasone furoate monohydrate, 50 mcg (MM; Nasonex), as a reference standard. This was a single center, single-dose, randomized, double-blinded parallel-group environmental exposure chamber study. Patients were primed at two 2-hour priming visits. Eligible patients were randomized to OLO, placebo spray, or MM, 2 sprays/nostril. Allergy symptoms (sneezing, runny, itchy, and stuffy nose) were rated by patients at 16 time points during 12 hours after dosing and patient satisfaction was assessed at 4 and 12 hours postdose. Safety was assessed by a review of adverse events, cardiovascular and nasal examination parameters. Four hundred twenty-five adult patients were randomized. OLO was superior to placebo spray in reducing total nasal symptoms (TNSS) within 30 minutes after dosing and maintained superiority for at least 12 hours (p < 0.05). The onset of MM was not observed until 150 minutes postdose and was smaller in magnitude compared with OLO. OLO was superior to both placebo spray (p < 0.0001) and MM (p < 0.05) in patient satisfaction. Treatment was well-tolerated with no safety concerns. OLO is superior to placebo spray and MM in reducing allergy symptoms; OLO has a rapid onset of action and a duration of effect of at least 12 hours.
MeSH term(s)	Administration, Intranasal ; Adolescent ; Adult ; Aged ; Anti-Allergic Agents/administration & dosage ; Anti-Allergic Agents/adverse effects ; Anti-Allergic Agents/therapeutic use ; Atmosphere Exposure Chambers ; Dibenzoxepins/administration & dosage ; Dibenzoxepins/adverse effects ; Dibenzoxepins/therapeutic use ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Mometasone Furoate ; Olopatadine Hydrochloride ; Pregnadienediols/administration & dosage ; Pregnadienediols/adverse effects ; Pregnadienediols/therapeutic use ; Rhinitis, Allergic, Seasonal/drug therapy ; Time Factors ; Treatment Outcome
Chemical Substances	Anti-Allergic Agents ; Dibenzoxepins ; Pregnadienediols ; Mometasone Furoate (04201GDN4R) ; Olopatadine Hydrochloride (2XG66W44KF)
Language	English
Publishing date	2007-09
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	1312445-6
ISSN	1088-5412
ISSN	1088-5412
DOI	10.2500/aap2007.28.3033
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1804: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: A global horizon scan of the future impacts of robotics and autonomous systems on urban ecosystems.

Goddard, Mark A / Davies, Zoe G / Guenat, Solène / Ferguson, Mark J / Fisher, Jessica C / Akanni, Adeniran / Ahjokoski, Teija / Anderson, Pippin M L / Angeoletto, Fabio / Antoniou, Constantinos / Bates, Adam J / Barkwith, Andrew / Berland, Adam / Bouch, Christopher J / Rega-Brodsky, Christine C / Byrne, Loren B / Cameron, David / Canavan, Rory / Chapman, Tim /

Connop, Stuart / Crossland, Steve / Dade, Marie C / Dawson, David A / Dobbs, Cynnamon / Downs, Colleen T / Ellis, Erle C / Escobedo, Francisco J / Gobster, Paul / Gulsrud, Natalie Marie / Guneralp, Burak / Hahs, Amy K / Hale, James D / Hassall, Christopher / Hedblom, Marcus / Hochuli, Dieter F / Inkinen, Tommi / Ioja, Ioan-Cristian / Kendal, Dave / Knowland, Tom / Kowarik, Ingo / Langdale, Simon J / Lerman, Susannah B / MacGregor-Fors, Ian / Manning, Peter / Massini, Peter / McLean, Stacey / Mkwambisi, David D / Ossola, Alessandro / Luque, Gabriel Pérez / Pérez-Urrestarazu, Luis / Perini, Katia / Perry, Gad / Pett, Tristan J / Plummer, Kate E / Radji, Raoufou A / Roll, Uri / Potts, Simon G / Rumble, Heather / Sadler, Jon P / de Saille, Stevienna / Sautter, Sebastian / Scott, Catherine E / Shwartz, Assaf / Smith, Tracy / Snep, Robbert P H / Soulsbury, Carl D / Stanley, Margaret C / Van de Voorde, Tim / Venn, Stephen J / Warren, Philip H / Washbourne, Carla-Leanne / Whitling, Mark / Williams, Nicholas S G / Yang, Jun / Yeshitela, Kumelachew / Yocom, Ken P / Dallimer, Martin

Nature ecology & evolution

2021 Volume 5, Issue 2, Page(s) 219–230

Abstract: Technology is transforming societies worldwide. A major innovation is the emergence of robotics and autonomous systems (RAS), which have the potential to revolutionize cities for both people and nature. Nonetheless, the opportunities and challenges ... ...

Abstract	Technology is transforming societies worldwide. A major innovation is the emergence of robotics and autonomous systems (RAS), which have the potential to revolutionize cities for both people and nature. Nonetheless, the opportunities and challenges associated with RAS for urban ecosystems have yet to be considered systematically. Here, we report the findings of an online horizon scan involving 170 expert participants from 35 countries. We conclude that RAS are likely to transform land use, transport systems and human-nature interactions. The prioritized opportunities were primarily centred on the deployment of RAS for the monitoring and management of biodiversity and ecosystems. Fewer challenges were prioritized. Those that were emphasized concerns surrounding waste from unrecovered RAS, and the quality and interpretation of RAS-collected data. Although the future impacts of RAS for urban ecosystems are difficult to predict, examining potentially important developments early is essential if we are to avoid detrimental consequences but fully realize the benefits.
MeSH term(s)	Biodiversity ; Cities ; Ecosystem ; Forecasting ; Humans
Language	English
Publishing date	2021-01-04
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2397-334X
ISSN (online)	2397-334X
DOI	10.1038/s41559-020-01358-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A global horizon scan of the future impacts of robotics and autonomous systems on urban ecosystems

Goddard, Mark A. / Davies, Zoe G. / Guenat, Solène / Ferguson, Mark J. / Fisher, Jessica C. / Akanni, Adeniran / Ahjokoski, Teija / Anderson, Pippin M.L. / Angeoletto, Fabio / Antoniou, Constantinos / Bates, Adam J. / Barkwith, Andrew / Berland, Adam / Bouch, Christopher J. / Rega-Brodsky, Christine C. / Byrne, Loren B. / Cameron, David / Canavan, Rory / Chapman, Tim /

Connop, Stuart / Crossland, Steve / Dade, Marie C. / Dawson, David A. / Dobbs, Cynnamon / Downs, Colleen T. / Ellis, Erle C. / Escobedo, Francisco J. / Gobster, Paul / Gulsrud, Natalie Marie / Guneralp, Burak / Hahs, Amy K. / Hale, James D. / Hassall, Christopher / Hedblom, Marcus / Hochuli, Dieter F. / Inkinen, Tommi / Ioja, Ioan Cristian / Kendal, Dave / Knowland, Tom / Kowarik, Ingo / Langdale, Simon J. / Lerman, Susannah B. / MacGregor-Fors, Ian / Manning, Peter / Massini, Peter / McLean, Stacey / Mkwambisi, David D. / Ossola, Alessandro / Luque, Gabriel Pérez / Pérez-Urrestarazu, Luis / Perini, Katia / Perry, Gad / Pett, Tristan J. / Plummer, Kate E. / Radji, Raoufou A. / Roll, Uri / Potts, Simon G. / Rumble, Heather / Sadler, Jon P. / de Saille, Stevienna / Sautter, Sebastian / Scott, Catherine E. / Shwartz, Assaf / Smith, Tracy / Snep, Robbert P.H. / Soulsbury, Carl D. / Stanley, Margaret C. / Van de Voorde, Tim / Venn, Stephen J. / Warren, Philip H. / Washbourne, Carla Leanne / Whitling, Mark / Williams, Nicholas S.G. / Yang, Jun / Yeshitela, Kumelachew / Yocom, Ken P. / Dallimer, Martin

Nature Ecology and Evolution

2021 Volume 5, Issue 2

Abstract	Technology is transforming societies worldwide. A major innovation is the emergence of robotics and autonomous systems (RAS), which have the potential to revolutionize cities for both people and nature. Nonetheless, the opportunities and challenges associated with RAS for urban ecosystems have yet to be considered systematically. Here, we report the findings of an online horizon scan involving 170 expert participants from 35 countries. We conclude that RAS are likely to transform land use, transport systems and human–nature interactions. The prioritized opportunities were primarily centred on the deployment of RAS for the monitoring and management of biodiversity and ecosystems. Fewer challenges were prioritized. Those that were emphasized concerns surrounding waste from unrecovered RAS, and the quality and interpretation of RAS-collected data. Although the future impacts of RAS for urban ecosystems are difficult to predict, examining potentially important developments early is essential if we are to avoid detrimental consequences but fully realize the benefits.
Keywords	Life Science
Subject code	710
Language	English
Publishing country	nl
Document type	Article ; Online
ISSN	2397-334X
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article: Letter: Antipyrine half life and clearance in clinical practice.

Whitling, B / Ullah, M / Meredith, P A

British medical journal

1976 Volume 2, Issue 6033, Page(s) 471

MeSH term(s)	Adult ; Antipyrine/metabolism ; Drug Interactions ; Female ; Half-Life ; Humans ; Male ; Phenytoin/metabolism
Chemical Substances	Phenytoin (6158TKW0C5) ; Antipyrine (T3CHA1B51H)
Language	English
Publishing date	1976-08-21
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	80088-0
ISSN	0007-1447 ; 0267-0623 ; 0959-8138 ; 0959-8146
ISSN	0007-1447 ; 0267-0623 ; 0959-8138 ; 0959-8146
DOI	10.1136/bmj.2.6033.471
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito